X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ABBOTT INDIA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ABBOTT INDIA CIPLA/
ABBOTT INDIA
 
P/E (TTM) x 40.5 41.1 98.6% View Chart
P/BV x 3.7 10.6 35.3% View Chart
Dividend Yield % 0.5 0.7 69.7%  

Financials

 CIPLA   ABBOTT INDIA
EQUITY SHARE DATA
    CIPLA
Mar-18
ABBOTT INDIA
Mar-18
CIPLA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs6636,110 10.9%   
Low Rs4793,996 12.0%   
Sales per share (Unadj.) Rs189.01,552.2 12.2%  
Earnings per share (Unadj.) Rs17.6188.8 9.3%  
Cash flow per share (Unadj.) Rs34.0196.4 17.3%  
Dividends per share (Unadj.) Rs3.0055.00 5.5%  
Dividend yield (eoy) %0.51.1 48.3%  
Book value per share (Unadj.) Rs176.7796.6 22.2%  
Shares outstanding (eoy) m805.1221.25 3,788.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.3 92.8%   
Avg P/E ratio x32.526.8 121.3%  
P/CF ratio (eoy) x16.825.7 65.2%  
Price / Book Value ratio x3.26.3 50.9%  
Dividend payout %17.129.1 58.5%   
Avg Mkt Cap Rs m459,724107,376 428.1%   
No. of employees `00023.63.3 710.7%   
Total wages/salary Rs m26,9013,937 683.3%   
Avg. sales/employee Rs Th6,446.19,929.3 64.9%   
Avg. wages/employee Rs Th1,139.41,185.1 96.1%   
Avg. net profit/employee Rs Th600.01,207.7 49.7%   
INCOME DATA
Net Sales Rs m152,19332,985 461.4%  
Other income Rs m3,5771,170 305.7%   
Total revenues Rs m155,76934,155 456.1%   
Gross profit Rs m28,2645,245 538.9%  
Depreciation Rs m13,228162 8,170.6%   
Interest Rs m1,14238 2,990.3%   
Profit before tax Rs m17,4706,215 281.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,5012,203 113.5%   
Profit after tax Rs m14,1664,012 353.1%  
Gross profit margin %18.615.9 116.8%  
Effective tax rate %14.335.4 40.4%   
Net profit margin %9.312.2 76.5%  
BALANCE SHEET DATA
Current assets Rs m108,14122,655 477.3%   
Current liabilities Rs m38,3226,681 573.6%   
Net working cap to sales %45.948.4 94.7%  
Current ratio x2.83.4 83.2%  
Inventory Days Days9765 149.8%  
Debtors Days Days7429 255.2%  
Net fixed assets Rs m109,411835 13,095.8%   
Share capital Rs m1,610213 757.7%   
"Free" reserves Rs m140,68216,715 841.6%   
Net worth Rs m142,29216,928 840.6%   
Long term debt Rs m36,6210-   
Total assets Rs m228,60624,162 946.1%  
Interest coverage x16.3163.7 10.0%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.71.4 48.8%   
Return on assets %6.716.8 39.9%  
Return on equity %10.023.7 42.0%  
Return on capital %10.036.9 26.9%  
Exports to sales %32.80-   
Imports to sales %00-   
Exports (fob) Rs m49,883NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,691369 14,025.9%   
Fx outflow Rs m21,0333,807 552.6%   
Net fx Rs m30,658-3,438 -891.7%   
CASH FLOW
From Operations Rs m14,6281,527 957.9%  
From Investments Rs m-8,540-2,148 397.5%  
From Financial Activity Rs m-3,855-1,024 376.3%  
Net Cashflow Rs m2,431-1,646 -147.7%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 75.0 27.7%  
Indian inst/Mut Fund % 12.2 7.9 154.4%  
FIIs % 23.7 0.1 23,700.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.1 153.2%  
Shareholders   161,166 18,270 882.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PLETHICO PHARMA  WOCKHARDT LTD.  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

CIPLA at 52 Week High; BSE 500 Index Flat (Market Updates)

Sep 19, 2018 | Updated on Sep 19, 2018

CIPLA share price has hit a 52-week high. It is presently trading at Rs 678. BSE 500 Index is up by 0.2% at 15,303. Within the BSE 500, CIPLA (up 1.6%) and DCM SHRIRAM (up 5.3%) are among the top gainers, while top losers are TECHNO ELECTRIC and JET AIRWAYS.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 19, 2018 (Close)

TRACK CIPLA

CIPLA - IPCA LABS COMPARISON

COMPARE CIPLA WITH

MARKET STATS